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SUMMARY

SARM1 is an inducible TIR-domain NAD+ hydrolase that mediates pathological axon degeneration. SARM1 is
activated by an increased ratio of NMN to NAD+, which competes for binding to an allosteric activating site.
When NMN binds, the TIR domain is released from autoinhibition, activating its NAD+ hydrolase activity. The
discovery of this allosteric activating site led us to hypothesize that other NAD+-related metabolites might
activate SARM1. Here, we show the nicotinamide analog 3-acetylpyridine (3-AP), first identified as a neurotoxin in the 1940s, is converted to 3-APMN, which activates SARM1 and induces SARM1-dependent NAD+
depletion, axon degeneration, and neuronal death. In mice, systemic treatment with 3-AP causes rapid
SARM1-dependent death, while local application to the peripheral nerve induces SARM1-dependent axon
degeneration. We identify 2-aminopyridine as another SARM1-dependent neurotoxin. These findings identify
SARM1 as a candidate mediator of environmental neurotoxicity and suggest that SARM1 agonists could be
developed into selective agents for neurolytic therapy.

INTRODUCTION
Axon degeneration is an essential feature of many neurodegenerative conditions. Sterile alpha and Toll/interleukin-1 receptor
motif-containing 1 (SARM1) is the central executioner of pathological axon degeneration, and a promising therapeutic target
for a wide range of neurological disorders (DiAntonio, 2019).
SARM1 also promotes neuronal cell death in response to oxygen-glucose deprivation, viral infection, and mitochondrial
toxins (Kim et al., 2007; Mukherjee et al., 2015; Mukherjee
et al., 2013; Summers et al., 2014). SARM1 is comprised of an
autoinhibitory N-terminal armadillo repeat (ARM) domain, tandem sterile-alpha motif (SAM) domains that mediate octamerization, and a C-terminal Toll/interleukin-1 receptor (TIR) domain.
This TIR domain is the original exemplar of a large family of TIR
domain nicotinamide adenine dinucleotide (NAD+) hydrolases,
conserved throughout all domains of life from bacteria and
archaea to plants and animals (Essuman et al., 2017, 2018;
Horsefield et al., 2019; Wan et al., 2019). In healthy neurons,
SARM1 is maintained in an autoinhibited state via multiple intraand intermolecular interactions (Shen et al., 2021), including
binding of the N-terminal ARM domain to the C-terminal TIRdomain (Summers et al., 2016). SARM1 autoinhibition is regulated by an allosteric binding site within the autoinhibitory ARM
domain that can bind either NAD+ (Jiang et al., 2020; Sporny

et al., 2020) or its precursor, nicotinamide mononucleotide
(NMN) (Figley et al., 2021). Axon injury leads to loss of the
NAD+ biosynthetic enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) (Gilley and Coleman, 2010), resulting in an increased NMN/NAD+ ratio that favors NMN binding to
the allosteric site (Figley et al., 2021). The switch from NAD+ to
NMN binding induces compaction of the autoinhibitory ARM
domain and permits the formation of TIR-TIR interactions that
activate the enzyme (Figley et al., 2021). The identification of
this allosteric binding pocket led us to hypothesize that metabolites with structural similarities to NMN and NAD+ might also
regulate SARM1 activation.
To explore whether additional NAD+-related metabolites activate SARM1, we searched the literature for neurotoxins with proposed mechanisms of action related to NAD+ metabolism. NAD+
biosynthesis in mammals largely occurs via the formation of
NMN from nicotinamide (Nam a.k.a. vitamin B3) by nicotinamide
phosphoribosyl transferase (NAMPT), followed by NAD+ synthesis from NMN, catalyzed by a nicotinamide mononucleotide adenyltransferase (NMNAT) enzyme (Revollo et al., 2004; Wang
et al., 2006). Studies of anti-metabolites starting in the 1940s
demonstrated that 3-acetylpyridine (3-AP), a Nam analog, is a
neurotoxin that causes degeneration in both the central and peripheral nervous systems (Beher et al., 1952; Desclin and Escubi,
1974; Hicks, 1955; Lopiano and Savio, 1986; Schulz et al., 1994;
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Wecker et al., 2017; Woolley and White, 1943). 3-AP is structurally identical to Nam except that a methyl group replaces Nam’s
amino group. Interestingly, 3-AP neurotoxicity is prevented by
co-administration of Nam. This led to the hypothesis that 3-AP
toxicity is due to the substitution of 3-AP for Nam in the NAD+
biosynthetic pathway, generating 3-acetylpyridine adenine dinucleotide (3-APAD), a potential NAD+ mimetic that subsequently
disrupts NAD+-dependent metabolic processes. While 3-AP is
converted to 3-APAD, it is not clear why neurons would be
particularly sensitive to this toxin. Severe vitamin B3 deficiency
(i.e., pellagra) decreases NAD+ levels and results in abnormalities
in many tissues throughout the body. We therefore hypothesized
that 3-AP introduction into the NAD+ biosynthesis pathway
causes neurodegeneration not via defects in NAD+ biosynthesis
or 3-APAD interference in NAD+-regulated processes, but rather
through inappropriate SARM1 activation.
To test this hypothesis, we investigated the impact of 3-AP on
neurons both in vitro and in vivo. We find that incubation of
cultured mouse dorsal root ganglion (DRG) neurons with 3-AP
leads to SARM1 activation, and SARM1-dependent NAD+
depletion, axon degeneration, and cell death. This neurotoxicity
requires both the conversion of 3-AP to 3-acetylpyridine mononucleotide (3-APMN), and a properly formed SARM1 allosteric
NMN-binding site. We also investigated the impact of 3-AP
in vivo and found that systemic exposure to 3-AP induces rapid
death in wild-type (WT) mice, but causes no obvious harm to
Sarm1 knockout (KO) mice. Local application of 3-AP to peripheral nerves leads to SARM1-dependent axon degeneration.
Finally, we assayed additional nicotinamide analogs and found
that 2-aminopyridine also triggers SARM1-dependent neurodegeneration. These findings identify SARM1 as a target of multiple
neurotoxins and a candidate mediator of environmental neurotoxicity in neurodegenerative disease. In addition, the identification of exogenous chemical SARM1 agonists may enable the
development of new methods for neurolytic therapy.
RESULTS
3-AP induces SARM1-dependent axon degeneration and
neuron death
3-AP is an analog of Nam in which the amino group is replaced
by a methyl group (Figure 1A). 3-AP was previously studied as
an antimetabolite in NAD+ biosynthesis and was assumed to
produce its effects by disrupting the conversion of Nam to
NMN and ultimately NAD+. Early studies showed that the administration of 3-AP to rabbits, dogs, mice, and rats resulted in
severe neurotoxicity and death that could be blocked by administration of Nam (Jolicoeur et al., 1982; Weller et al., 1992).
The recent demonstration that NMN binds to an allosteric site
in SARM1 to activate its NAD+ hydrolase activity and promote
axon degeneration led us to examine the role of SARM1 in 3-AP
toxicity. We cultured WT mouse embryonic DRG neurons and
treated them with varying doses of 3-AP. We measured axonal
integrity at multiple time points after 3-AP addition and found
that axons remain intact at low doses, but begin to degenerate
slowly when exposed to 250 mM 3-AP. At doses above 250 mM,
axons rapidly degenerate at a rate similar to that observed after
transection (Figures 1B and 1D). We also measured neuronal
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death using the MTT assay and found that 3-AP treatment causes
neuronal death at similar doses (Figure 1C).
SARM1 is required for pathological axon degeneration downstream of multiple insults and, when activated throughout the
cell, also induces neuronal cell death (Figley and DiAntonio,
2020). We tested whether 3-AP-mediated axon degeneration
and neuronal death also require SARM1 by treating Sarm1 KO
DRG neurons with escalating doses of 3-AP. Surprisingly, we
found that 3-AP had no effect on neurons lacking SARM1 (Figures 1C and 1D), even at extremely high doses (e.g., 1 mM).
These experiments demonstrate that 3-AP mediated neurotoxicity requires SARM1.
When SARM1 is activated by axonal injury, its potent NAD+ hydrolase activity depletes the axon of NAD+ and produces cyclic
adenosine diphosphate ribose (cADPR), a sensitive biomarker
of SARM1 activity (Essuman et al., 2017; Sasaki et al., 2020).
These metabolic changes incite energetic catastrophe and subsequent axon fragmentation (Gerdts et al., 2015). To determine
whether 3-AP activates SARM1 NAD+ hydrolase activity, we
measured relevant metabolites in neurons following addition of
3-AP (300 mM). We found substantial NAD+ and ATP depletion
and an 10-fold increase in cADPR at 4 hr post 3-AP addition
(Figure 1E). These metabolite changes are similar to those
observed after axotomy and indicate that SARM1 is activated
by 3-AP. To confirm the SARM1-dependence of 3-AP neurotoxicity, we performed similar metabolite measurements in 3-APtreated Sarm1 KO neurons and found no significant changes in
the levels of NAD+, ATP, or cADPR (Figure 1E). Taken together,
these results demonstrate that 3-AP stimulates metabolite
changes consistent with SARM1 activation, and that 3-AP neurotoxicity is dependent on SARM1.
Neurotoxicity caused by 3-AP requires its conversion to
3-APMN
While the metabolic changes induced by 3-AP are almost identical to those caused by axotomy, there is one telling difference.
Following axotomy, NMN levels rise because axonal NMNAT2 is
lost (Di Stefano et al., 2015). In contrast, 3-AP intoxication leads
to a greater than 50% decline in NMN within four hours (p <
0.001, n = 3). As NMN is synthesized from Nam and phosphoribosyl pyrophosphate (PRPP) by the enzyme NAMPT, this finding
suggests that 3-AP competes with Nam for NAMPT, and thereby
inhibits the production of NMN. Early studies of 3-AP neurotoxicity in mice and other species provide additional evidence for
competition between 3-AP and Nam. These studies showed
that co-administration of Nam prevented 3-AP-induced neurotoxicity and death (Jolicoeur et al., 1982; Weller et al., 1992).
To assess whether Nam influences 3-AP-mediated axon degeneration, we pretreated DRG neurons with increasing amounts of
Nam before addition of 3-AP. We found that Nam pretreatment
reduces 3-AP-induced axon degeneration in a dose-dependent
manner (Figure 2A), suggesting that Nam blocks the metabolism
of 3-AP into a compound toxic to axons. A similar protective effect was observed for neuronal cell death (as quantified in Figure 1C), confirming the concordance of soma and axonal demise
in response to global SARM1 activation (Gerdts et al., 2013;
Summers et al., 2014). As an independent test of this hypothesis,
we treated neurons with 3-AP and FK866, an inhibitor of NAMPT.
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Figure 1. 3-AP causes SARM1-dependent
neurotoxicity
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(A) Diagram of nicotinamide (Nam) and 3-AP
metabolism by NAMPT and NMNAT. X represents
amino (Nam) or methyl (3-AP) group.
(B) WT and Sarm1 KO DRGs were treated with
3-AP (300 mM) at DIV7. Representative images
of axons from WT and Sarm1 KO cultured DRG
neurons at 0, 6, 24, 48 hr after 3-AP treatment show
axon degeneration. Scale bars, 20 mm.
(C) WT and Sarm1 KO embryonic DRGs were
treated with 3-AP for 12 hr and MTT assays were
performed to quantify cell viability at DIV7. Boxes
represent the interquartile range with horizontal
lines indicating the median and whisker lines extending to the maximum and minimum values.
Statistical significance was determined by oneway ANOVA test, comparing to cell viability of each
genotype treated with 0 mM 3-AP. ****p < 0.0001.
(D) WT (top) and Sarm1 KO (bottom) DRGs were
treated with 3-AP (300 mM) at DIV7. Axon degeneration index was measured at indicated times
after 3-AP treatment. Data with error bars correspond to Mean ± SD. Statistical significance was
determined by one-way ANOVA tests, comparing
to control degeneration index at time 0 hr. ****p <
0.0001.
(E) WT or Sarm1 KO DRG neurons were treated
with 3-AP at DIV7. Metabolites were quantified by
LC-MS/MS at indicated times after treatment. Data
with error bars correspond to Mean ± SD. Statistical significance was determined by one-way
ANOVA tests, comparing to metabolite of each
genotype at time 0 hr. **p < 0.01; ***p < 0.001;
****p < 0.0001.

D

NAMPT inhibition blocks the neurotoxic actions of 3-AP (Figure 2B), supporting the idea that 3-AP is metabolized to a toxic
derivative via a pathway involving NAMPT.
To identify the 3-AP derivative responsible for SARM1 activation and axon degeneration, we first developed mass spectrometry methods to detect 3-APMN and 3-APAD in neurons (Figures
S1A and S1B). We isolated metabolites from DRG neurons

at various time points following 3-AP
treatment and analyzed them by LC-MS/
MS. Both 3-APMN and 3-APAD levels
peak within 2 hr of 3-AP addition, with
3-APMN detectable slightly earlier than
3-APAD, consistent with a precursorproduct relationship (Figures 2C and 2D).
Notably, they both appear several hours
before the increase of the SARM1-derived
product cADPR (Figure 2E).
To directly demonstrate the involvement of NAMPT/NMNAT activity in the
production of these metabolites, we
pre-treated neurons with FK866 prior to
3-AP addition. In FK866-treated neurons,
3-APMN and 3-APAD remain at baseline,
and cADPR levels do not increase
(Figures 2C–2E). Together with results
demonstrating that FK866 blocks axon degeneration in 3-APtreated neurons, these data strongly support the hypothesis
that 3-AP is metabolized by NAMPT alone or in combination
with other NAD+ biosynthetic enzymes (e.g., NMNAT) to produce
a SARM1 agonist.
SARM1-mediated axon degeneration caused by mechanical
or chemical insults can be blocked by overexpression of
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Figure 2. The conversion of 3-AP to 3-APMN is required for neurotoxicity
(A) Nam inhibits 3-AP-induced axon degeneration. WT DRG neurons were pretreated overnight with Nam at 0, 50, 100 or 200 mM on DIV7, then treated with 3-AP
(500 mM). Axon degeneration was quantified at indicated times following treatment. Data with error bars correspond to Mean ± SD. Statistical significance was
determined by one-way ANOVA tests (compared to 0 hr). ***p < 0.001; ****p < 0.0001.
(B) NAMPT inhibitor FK866 protects neurons against 3-AP toxicity. WT DRG neurons were pretreated overnight with FK866 at 0, 25, 50 or 100 nM, then treated
with 3-AP (300 mM). Axon degeneration was quantified after 3-AP addition. Data with error bars correspond to Mean ± SD. Statistical significance was determined
by one-way ANOVA test (compared to 0 hr). ***p < 0.001; ****p < 0.0001.
(C–E) Metabolites in WT neurons treated as indicated were measured using LC-MS/MS. Data with error bars correspond to Mean ± SD.
(F) NMNAT1 prevents 3-AP-induced axon degeneration. WT DRG neurons were infected with NMNAT1 lentivirus at DIV3 and treated with 3-AP (300 mM) at DIV7.
Data with error bars correspond to Mean ± SD. Statistical significance was determined by one-way ANOVA test (compared to 0 hr). ***p < 0.001; ****p < 0.0001.
(G) NMN deamidase fails to prevent 3-AP-induced axon degeneration. WT DRG neurons were infected with NMN deamidase (NMN DD) lentivirus at DIV3 and
treated with 3-AP (300 mM) at DIV7. Data with error bars correspond to Mean ± SD. Statistical significance was determined by one-way ANOVA test (compared to
0 hr). **p < 0.01; ***p < 0.001; ****p < 0.0001.
See also Figure S1.
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NMNAT1 (Araki et al., 2004) or the bacterial enzyme NMN deamidase (Di Stefano et al., 2015). The axon protection provided by
these enzymes presumably reflects their ability to reduce axonal
NMN levels via conversion of NMN to NAD+ or NaMN, respectively. When NMN levels are low, it is less likely to bind the
SARM1 allosteric site and induce the conformational change
that activates SARM1 hydrolase activity and subsequent axon
degeneration. To investigate which 3-AP-derived metabolite activates SARM1, we tested whether these NMN-consuming enzymes could also ameliorate 3-AP neurotoxicity. We find that
NMNAT1 prevents 3-AP-induced increases in cADPR and
axon fragmentation (Figures 2E and 2F). In contrast, axons of
neurons expressing NMN deamidase remain susceptible to
3-AP and high levels of cADPR are produced (Figures 2E and
2G). In each case, 3-AP-stimulated neuron cell death was
affected similarly as axon degeneration. Importantly, 3-APMN
and 3-APAD are still generated in the presence of NMN deamidase (Figures 2C and 2D). This is consistent with its deamidase
activity, as 3-AP derivatives lack the amino group that is the
target of this enzyme in Nam. In contrast, NMNAT1 overexpression strongly blunts the rise of both 3-APMN and cADPR while
maintaining robust production of 3-APAD (Figures 2C–2E), indicating that SARM1 is not activated when 3-APMN levels are low.
These results support the hypothesis that 3-APMN is the 3-AP
derivative that directly activates SARM1 to drive neuronal cell
death and axon fragmentation.
3-AP can be converted to 3-APMN and 3-APAD by
NAMPT and NMNAT
The inhibition of NAMPT and overexpression of NMNAT1 both
prevent 3-AP-mediated SARM1 activation and neuronal toxicity.
These results, along with the structural similarities between Nam
and 3-AP and their respective metabolites, NMN and 3-APMN,
led us to hypothesize that NAMPT converts 3-AP to 3-APMN,
which then acts as an NMN mimetic to directly activate
SARM1-mediated axon degeneration. We first tested whether
NAMPT can convert 3-AP to 3-APMN using an in vitro biochemical assay. NAMPT enzyme was produced in E. coli and the purified enzyme was incubated with 3-AP and its cofactors PRPP
and ATP. We used LC-MS/MS to detect the compound generated in this reaction, which was determined to be 3-APMN
(Figure S1A). We next examined whether this 3-APMN could
be converted to 3-APAD by NMNAT1. We produced and purified
NMNAT1 and performed reactions in which NAMPT and
NMNAT1 together were combined with 3-AP, PRPP and ATP.
We detected a compound that was identified as 3-APAD using
a 3-APAD standard and LC-MS/MS (Figure 3A and S1B). The
production and identification of these two 3-AP-derived products confirms that 3-AP can be metabolized by the NAMPT/
NMNAT pathway in a parallel fashion to Nam.
SARM1 also synthesizes 3-APAD from 3-AP and NAD+
via base exchange
SARM1 possesses base exchange activity in addition to its hydrolase activity (Zhao et al., 2019), in which the ADPR moiety
of NAD+ is condensed with an acceptor molecule. This reaction
presents a pathway for the direct production of 3-APAD
by SARM1 using 3-AP as the acceptor. To test this idea, we
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performed biochemical assays using SARM1 purified from
HEK293T cells. SARM1 was incubated with NAD+ and 3-AP
and the reaction products were analyzed using HPLC and LCMS/MS. We detected the formation of 3-APAD by SARM1 (Figure 3B) that required both NAD+ and 3-AP with the amount of
product dependent on the concentrations of both precursors.
(Figure 3C and 3D). The formation of 3-APAD from 3-AP is
consistent with the SARM1 catalyzed transfer of the NAD+
ADPR moiety to 3-AP via a base exchange reaction (Zhao
et al., 2019). This represents a second route for production of
3-APAD from 3-AP that is in addition to the NAMPT/ NMNAT1
pathway (Figure 3A).
To determine whether this SARM1-mediated base exchange
reaction occurs in neurons, we sought to analyze the generation
of 3-APAD in neurons lacking the NAMPT/NMNAT pathway.
Because Nmnat2 knockout mice are not viable (Gilley and Coleman, 2010), we used DRG neurons from Sarm1/Nmnat2 doubleknockout (dKO) mice for these experiments. We found that
Sarm1/Nmnat2 dKO neurons treated with 3-AP do not produce
3-APAD. This demonstrates that 3-APAD production in cultured
DRG neurons requires NMNAT2 but does not require its paralogs
NMNAT1 or NMNAT3 (Figure 3E). To further examine the import
of the SARM1-mediated base exchange reaction, we infected
Sarm1/Nmnat2 dKO neurons with lentivirus expressing SARM1
at DIV3 and examined metabolites at DIV7. We found that reintroducing SARM1 to these neurons restores 3-APAD production (Figure 3E), demonstrating that SARM1 carries out the
base exchange reaction in neurons. Indeed, Sarm1 KO neurons
treated with 3-AP produce much less 3-APAD than do wild-type
neurons (Figure 3E), indicating that SARM1 is a major contributor
to 3-APAD synthesis. The residual 3-APAD produced in Sarm1
KO neurons treated with 3-AP demonstrates that the NAMPT/
NMNAT pathway also actively produces 3-APAD from 3-AP.
Together, these results show that both SARM1-catalyzed base
exchange activity and NAMPT/NMNAT2 contribute to 3-APAD
synthesis in neurons.
3-APMN activates purified SARM1 in vitro
The results from manipulating the NAMPT/NMNAT pathway and
SARM1 in neurons support the hypothesis that 3-APMN can
activate SARM1. To test whether SARM1 is directly activated
by 3-APMN, we purified SARM1 on Strep-tag beads and incubated it with purified 3-APMN (Figure S2) in the presence of
the pyridine conjugate PC6, a fluorescent probe of SARM1 hydrolase activity (Li et al., 2021; Zhao et al., 2019). We measured
the reaction in real time by following the fluorescence output
signal and found that SARM1 hydrolase activity increases with
3-APMN concentration (Figure 4A). We determined the activation constant of the reaction (KA) to be 44 mM, which is slightly
lower than the reported dissociation constant (KD) for NAD+
binding to the SARM1 ARM domain (Figley et al., 2021). These
results indicate that 3-APMN interacts directly with SARM1 to
activate its NAD+ hydrolase activity.
To determine whether 3-APMN activates SARM1 via the same
binding pocket responsible for NMN-mediated SARM1 activation, we examined several SARM1 mutants in which this allosteric pocket is disrupted (Figley et al., 2021). We tested
SARM1 W103A, R157A and K193R, three mutants in the
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Figure 3. 3-APAD can be generated by either NAMPT-NMNAT pathway or SARM1-mediated base exchange reaction
(A) 3-APAD is synthesized in 3-AP dose-dependent manner using in vitro reactions containing purified NAMPT and NMNAT1. Boxes represent the interquartile
range with horizontal lines indicating the median and whisker lines extending to the maximum and minimum values.
(B) Representative HPLC trace demonstrating the 3-AP dose-dependent production of 3-APAD in vitro via SARM1-mediated base exchange reaction.
(C) In vitro 3-APAD production by SARM1 is dependent on NAD+ concentration at a fixed 3-AP concentration (40 mM). Boxes represent the interquartile range with
horizontal lines indicating the median and whisker lines extending to the maximum and minimum values.
(D) In vitro 3-APAD production by SARM1 is dependent on 3-AP concentration at fixed NAD+ concentration (50 mM). Boxes represent the interquartile range with
horizontal lines indicating the median and whisker lines extending to the maximum and minimum values.
(E) 3-APAD in neurons is produced by both SARM1 and the NAMPT/NMNAT pathway. WT, Sarm1 KO (SKO) and Nmnat2/ Sarm1 double knockout (dKO) neurons
were treated with 3-AP (300 mM) and metabolites were analyzed after 4 hr of treatment. Infection of dKO or SKO neurons with a SARM1 lentivirus increases the
amount of 3-APAD detected. Boxes represent the interquartile range with horizontal lines indicating the median and whisker lines extending to the maximum and
minimum values.
See also Figure S1.

allosteric pocket that are not activated in response to elevated
NMN (Figley et al., 2021). Tellingly, lentiviral expression of
wild-type SARM1 restores 3-AP-induced axon degeneration to
Sarm1 KO DRG neurons, whereas the axons of 3-AP-treated
neurons expressing any of the three SARM1 allosteric pocket
mutants remain intact (Figure 4B). Hence, the N-terminal allosteric site that binds NMN and NAD+ is necessary for 3-APinduced SARM1 activation.
3-AP neurotoxicity in mice requires SARM1
Early animal experiments showed that intraperitoneal (IP) injection of 3-AP leads to rapid death accompanied by extensive lesions throughout the nervous system (Desclin and Escubi,
1974). To investigate the role of SARM1 activation in 3-AP
toxicity in vivo, we administered 3-AP via IP injection to WT
and Sarm1 KO mice. Wild-type mice treated with 275 mg/kg
3-AP generally survive, but those treated with 400 mg/kg 3-AP
die rapidly. In contrast, Sarm1 KO mice survive and have no
obvious phenotype following treatment with up to 500 mg/kg
3-AP, a dose that is rapidly lethal for wild-type mice (Figure 5A).
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To assess SARM1 activation in vivo, we monitored levels
of cADPR, a SARM1 biomarker. Following IP treatment with
275 mg/kg, levels of cADPR in the sciatic nerve increase 3- to
4-fold by 3 days postadministration (Figure 5B). Similar injections into Sarm1 KO mice caused no alteration in cADPR levels,
confirming the SARM1-dependence of cADPR production.
To examine the effect of 3-AP on axon degeneration and to
circumvent systemic toxicity, we performed local administration
by applying a Surgifoam wrap soaked in 500 mM 3-AP (or saline
control) to surgically exposed sciatic nerve. After such treatment, WT mice rapidly develop an abnormal gait, favoring their
untreated leg, and fail to splay the toes of their 3-AP-treated
paw in the usual fashion. Seven days after local treatment, the
tibial nerves distal to the 3-AP treatment site were dissected
and analyzed. 3-AP treated nerves from WT mice showed a dramatic loss of axons compared to the contralateral nerve or saline-treated nerve, demonstrating the local effect of 3-AP. In
contrast to the findings in WT mice, treated nerves from Sarm1
KO mice were well protected from axon loss (Figures 5C–5E).
Quantification of axons in the tibial nerve shows a substantial
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Figure 4. 3-APMN directly activates SARM1
via its allosteric binding site
(A) Fold-increase in rate of SARM1 hydrolase activity with increasing concentrations of 3-APMN
(Mean ± SD, n = 3), as measured by PC6 fluorescence.
(B) 3-APMN activates SARM1 via its NMN/NAD+binding pocket in the N-terminal domain. Sarm1
KO DRG neurons were infected with lentivirus expressing W103A, R157A or K193R SARM1 mutants or controls (GFP and wild-type SARM1) at
DIV3. Axon degeneration indexes were determined at indicated times after 3-AP (300 mM)
administration. Boxes represent the interquartile range with horizontal lines indicating the median and whisker lines extending to the maximum and minimum
values. Statistical significance was determined by one-way ANOVA tests, comparing to degeneration index of 3-AP+GFP at each time point. ****p < 0.0001.
See also Figure S2.

axon loss in the 3-AP-treated nerves (Figure 5E). We also
examined the sciatic nerve to explore whether degeneration proceeded retrograde to the site of 3-AP application. We found that
axon degeneration only occurs distal to the site of application,
with no detectable axon damage in the proximal sciatic nerve
(Figure 5F). The triggering of localized SARM1-dependent axon
degeneration in vivo by restricted 3-AP application suggests
that such a SARM1-activating neurotoxin may be useful as a
neurolytic agent.
Additional nicotinamide analogs induce SARM1dependent axon degeneration
The pyridine ring is a common component of many drugs and industrial chemicals, suggesting that many of these compounds
could also be neurotoxic in a SARM1-dependent fashion. To
test whether other pyridine derivatives also bind and activate
SARM1, we tested 2-, 3-, and 4-aminopyridines and 2- 3-, and
4- acetylpyridines in our axon degeneration and SARM1 activation assays. Interestingly, we found that 2-aminopyridine causes
axon degeneration in WT but not in Sarm1 KO neurons, similar to
3-AP (Figure S3A), whereas the other related compounds failed
to trigger axon degeneration even at very high doses (800 mM)
(Figure S3B). Hence, multiple pyridine compounds exhibit
SARM1-dependent toxicity, identifying SARM1 as a candidate
target for the many toxins with related chemical structures
(Buonvicino et al., 2018). Indeed, a recent preprint demonstrated
that the rodenticide vacor, which has a pyridine ring, induces
SARM1-dependent toxicity (Loreto et al., 2020).
DISCUSSION
A major advance in our understanding of programmed axon
degeneration was the recent discovery that SARM1, the central
axon executioner, is activated by a rise in the intracellular ratio of
the nicotinamide metabolites NMN to NAD+ (Figley et al., 2021).
Here we capitalize on this breakthrough to expose the mechanism of a decades-old biological riddle, the dramatic neurotoxicity of 3-AP and related compounds (Woolley and White,
1943). Our results support a model in which 3-AP is metabolized
to produce the NMN mimetic 3-APMN which binds the allosteric
pocket of SARM1, thereby activating its NADase activity and
initiating pathological axon degeneration. The identification of

SARM1 as a direct target of neurotoxins has two important implications. First, these findings suggest that SARM1 activation by
environmental toxins is a potential contributor to neurodegenerative disorders. Second, the identification of selective SARM1
agonists may lead to the development of new approaches for
therapeutic neurolysis.
The nervous system employs an active program of axon selfdestruction, also known as Wallerian degeneration, to facilitate
the orderly clearance of axon segments damaged by trauma or
disease. The choice between axon maintenance and dissolution
is chiefly made by the TIR-containing NAD+ hydrolase SARM1
(Figley and DiAntonio, 2020). Healthy neurons maintain SARM1
in an autoinhibited state, but injury- or disease-associated attrition of the NAD+ synthetase NMNAT2 (Gilley and Coleman,
2010) induces rapid NAD+ depletion by SARM1 leading to metabolic catastrophe and axon fragmentation. Thus NAD+ homeostasis is crucial for axon maintenance as well as overall neuronal
health (Gerdts et al., 2015). NAD+ is generated from Nam in two
steps: the rate-limiting conversion of Nam to NMN by NAMPT, followed by synthesis of NAD+ from NMN by NMNAT2 and its paralogs (Sauve, 2008). NMN and NAD+ compete to bind an allosteric
pocket that modulates SARM1 autoinhibition, rendering SARM1 a
metabolic sensor that responds to an elevated NMN/NAD+ ratio
(Figley et al., 2021; Jiang et al., 2020; Sporny et al., 2020). As
such, experimental manipulations that alter the apparent concentration of either metabolite, whether by short-circuiting the usual
synthesis pathway or by interjecting an NMN mimetic, directly
affect SARM1 activity and its consequences (Di Stefano et al.,
2017; Sasaki et al., 2009; Zhao et al., 2019).
It was first observed three quarters of a century ago that treatment with a nicotinamide analog, 3-AP, induces rapid hindlimb
paralysis and death in mice, symptoms that could be prevented
by sufficient prior fortification with nicotinic acid or Nam (Woolley
and White, 1943). 3-AP-treated animals develop widespread
nervous system lesions, particularly in brainstem nuclei, and
consecutive treatment with 3-AP and Nam was eventually developed into a useful method for specific ablation of the inferior olive
in rodents (Desclin and Escubi, 1974; Rondi-Reig et al., 1997;
Wecker et al., 2017). However, the mechanism of 3-AP neurotoxicity remained unknown. Here we present comprehensive evidence demonstrating that 3-AP injures the nervous system by
directly activating SARM1 and inducing Wallerian degeneration.
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Figure 5. 3-AP neurotoxicity in mice is mediated by SARM1
(A) Survival curve of WT and Sarm1 KO (SKO) mice injected IP with indicated doses of 3-AP (n = 5). Mice injected with PBS (control) showed no lethality (n = 3), and
SKO mice injected with 275 mg/kg 3-AP showed no lethality (n = 5).
(B) cADPR levels in sciatic nerve of WT and SKO mice at 3 days post IP injection with PBS or 3-AP (275 mg/kg). Statistical significance was determined by oneway ANOVA tests, comparing to cADPR of WT PBS condition. Boxes represent the interquartile range with horizontal lines indicating the median and whisker lines
extending to the maximum and minimum values. ****p < 0.0001.

(legend continued on next page)
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The profound invulnerability of both Sarm1/ mice and
Sarm1/ cultured neurons to 3-AP first alerted us to the
SARM1-dependence of 3-AP toxicity and lead to the straightforward hypothesis that 3-APMN, a 3-AP metabolite nearly identical to NMN, hijacks the SARM1 pathway by binding the
enzyme’s allosteric site and triggering its prodegenerative activity. Analysis of 3-AP-treated wild-type neurons confirmed the
presence of 3-APMN and its derivative 3-APAD, as well as the
specific SARM1 activity marker, cADPR. Decisively establishing
our thesis required two further key pieces of evidence: 1) the
demonstration that 3-APMN directly binds and activates
SARM1, and 2) that manipulating 3-APMN levels in 3-APexposed neurons correspondingly alters SARM1 activity and
its toxic consequences. Both of these criteria were demonstrated using both in vitro and in vivo methods, elucidating the
mechanism of action of this long-studied neurotoxin. Moreover,
this proposed mechanism of SARM1-dependent 3-AP toxicity
surely applies to other structural-similar pyridine derivatives,
and we identified 2-aminopyridine as such a case. We suggest
that SARM1 activation may be a common cause of neurotoxicity
caused by pyridine compounds.
In the course of demonstrating the SARM1-dependence of
3-AP toxicity in vivo, we exposed peripheral nerves to 3-AP in order to determine whether the toxin could stimulate localized neurodegeneration. Prior in vivo studies of 3-AP were confined to
systemic administration. A key motivation for these experiments
was to explore the potential utility of 3-AP or other pyridines for
therapeutic neurolysis—the application of physical or chemical
agents to effect temporary degeneration of nerves distal to a targeted lesion (Filippiadis et al., 2019). Purposeful nerve destruction can be appropriate for a variety of severe pain conditions,
especially visceral pain associated with pancreatic cancer, trigeminal neuralgia, or facetogenic and vertebral pain (D’Souza
and Strand, 2021). Gratifyingly, we found that local application
of 3-AP caused rapid degeneration of the exposed nerve
fibers without apparent systemic harm. Further, the 3-AP injury
signaling did not progress anterogradely, thus sparing the
proximal nerve. Currently, chemical neurolysis is achieved by injecting phenol or ethanol, nonspecific noxious agents that can
damage non-neuronal tissues. While both chemicals are highly
efficacious, ethanol injection produces severe burning pain
and phenol may cause systemic complications such as nausea,
cardiovascular depression, and cardiac arrhythmias (Weksler
et al., 2007). Therefore, a neuroselective agent could expand
the option of neurolysis beyond its current limited indications
to more broadly treat neuropathic pain. Because neurolytic
techniques specifically exploit Wallerian degeneration to ablate
axons (D’Souza and Strand, 2021; Filippiadis et al., 2019), we
propose that a SARM1 agonist fits well with this application.

Thus, in the best traditions of medicine, the solution to a toxicological mystery may be adapted into a useful therapeutic.
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This study

N/A
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This paper does not contain original code.
Any additional information required to reanalyze the data is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All experiments were performed in accordance with the protocols of the Institutional Animal Care and Use Committee of Washington
University in St. Louis and the guidelines for the Care and Use of Laboratory Animals of the National Institutes of Health. Mice were
housed on a 12 hr light dark cycle with less than 5 mice per cage and with water and food available at all times. Male and female mice
were used for all experiments. 5-week old mice were used for IP injection and 5-6-month old mice were used for Surgifoam wrap
treatments. Sarm1 KO mice were a gift from Macro Colonna at Department of Pathology and Immunology, Washington University
School of Medicine in St. Louis (Szretter et al., 2009), and C57BL/6 mice were purchased from Jackson Laboratory.
Mammalian cell lines
HEK293T cells (ATCC) and HEK293T cells stably-expressing Nicotinamide Riboside Kinase 1 (NRK1) (Essuman et al., 2017) were
cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Thermofisher Scientific) supplemented with 10% FBS, penicillin/streptomycin and glutamine. Both cell lines were cultured in a 37 C incubator with 5% CO2. Cells were passed every 3-4 days using
0.05% Trypsin containing 0.02% EDTA (GIBCO).
Bacterial cultures
StrepTag-NAMPT and StrepTag-NMNAT1 were cloned into pET30a+ plasmids. Plasmids were transformed into T7 Express Competent E. coli (New England BioLabs) as described previously (Essuman et al., 2017). Single colonies were selected and grown overnight
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at 37 C. Cultures were diluted in LB media, IPTG (1 mM) was added at A600 = 0.6, and bacteria were induced for another 4 hr before
harvest. See ‘NAMPT and NMNAT1 production in E. coli’ section for subsequent protein purification.
DRG neuron culture
Mouse DRG culture was as described previously (Sasaki et al., 2009). Mouse DRGs were dissected at embryonic day 13.5. Approximately 50 ganglia were collected from each embryo and dissociated in 0.05% Trypsin containing 0.02% EDTA (GIBCO) at 37 C for
20 min. The DRG neurons were washed 3 times with DRG culture medium after incubation with Trypsin. Cells were seeded as spot
cultures in 96-tissue culture plates (Corning) coated with 0.1 mg/ml poly-D-lysine and 0.1 mg/ml laminin. They were cultured in Neurobasal (GIBCO) containing 2% B27 (Invitrogen), 100 ng/ml 2.5S NGF (Harlan Bioproducts), and 1 mM 5-fluoro-20 -deoxyuridine/1 mM
uridine. The culture medium was exchanged with fresh DRG culture medium every 2-3 days. Lentiviruses were added 3 days after
seeding (DIV3).
METHODS DETAILS
Lentivirus production
Lentivirus production was performed as described previously (Araki et al., 2004). HEK293T cells were seeded with the density of 1 3
106 in 35 mm well tissue culture plate (Corning). Transfection was performed one day after seeding the cells. Lentiviral constructs
were co-transfected with VSV-G and psPAX2 lentiviral packing vectors. Two days after transfection, lentiviruses were collected
from culture supernatant and concentrated with Lenti-X concentrator (Clontech). Lentiviruses were suspended in 1/10 volume of culture supernatant with PBS, and stored at 80 C.
Quantification of axon degeneration
After culture for 7 days, axotomy was performed by cutting DRG axons manually with a razor blade. After axon transection, brightfield images of distal axons were taken using the Operetta automated imaging system (PerkinElmer). Axon degeneration indexes
were calculated from these bright-field images using ImageJ (NIH). The axon degeneration index was calculated as the ratio of fragmented axon areas as previously described (Sasaki et al., 2009). Indexes were calculated as the average of six fields per well.
NAMPT and NMNAT1 production in E. coli
See ‘Experimental Model and Subject Details’ section for bacteria culture procedures. Protein purification was performed using
StrepTactin Megbeads (Cube Biotech). The beads were washed with HEPES buffer (50 mM HEPES/NaOH pH 7.5, 300 mM sodium
chloride, 20% glycerol with EDTA-free protease inhibitors) and proteins were eluted with 5 mM dethiobiotin (50 mM HEPES/NaOH pH
7.5, 300 mM sodium chloride, 20% glycerol, 5 mM dethiobiotin with EDTA-free protease inhibitors). Protein concentrations were
determined by Pierce BCA Protein Assay (Thermofisher Scientific).
SARM1 protein purification from mammalian cells
A HEK293T cell line stably expressing NRK1 was used to produce SARM1 protein as previously described (Essuman et al., 2017). In
short, plasmid containing N-terminal StrepTag-SARM1 was transfected into NRK1-HEK293T cells using X-tremeGENE reagent
(Millipore Sigma). After 2 days, the cells were harvested and re-suspended with binding buffer (100 mM Tris-HCL pH 8, 150 mM sodium chloride, 0.01% Tween-20 with EDTA-free protease inhibitors (Pierce)). After sonication, cell debris was removed by centrifugation at 15,000 xg for 10 minutes. Soluble lysates were then mixed with StrepTactin Megbeads (Cube Biotech) equilibrated with the
same binding buffer. After incubation at 4 C for 60 minutes, beads were washed with washing buffer (25 mM HEPES, pH 7.5 and
150 mM NaCl with EDTA-free protease inhibitors). If elution was not required, SARM1 containing beads were re-suspended in
washing buffer with addition of 1 mM TCEP and stored at 80 C before further use.
Base exchange assay and metabolite extraction for HPLC and LC-MS/MS
SARM1 protein was eluted from the beads by incubating for 15 min at 4 C degree in eluting buffer (25 mM HEPES/NaOH pH 7.5,
150 mM sodium chloride, 20% glycerol, 5 mM desthiobiotin with EDTA-free protease inhibitors). In a typical assay, 500 ng
SARM1 protein was mixed with 50 mM or 100 mM NAD+ and ascending concentrations of 3-AP (20 mM, 40 mM, 60 mM). The reactions
were incubated at 37 C degree for 1 hr in a total reaction volume of 50 ml. For HPLC analysis, the reaction was stopped by addition of
50 ml 0.5 M perchloric acid (HClO4) and then neutralized with 3 M potassium carbonate (K2CO3). After neuralization and removal of
precipitate by centrifugation, 50 ml supernatant was loaded onto HPLC. For LC-MS/MS analysis, the reaction was stopped by addition of 50 ml 50% methanol and metabolites were extracted using 1/3 total volume of chloroform. The aqueous phase was lyophilized
and stored at 20 C for LC-MS/MS analysis.
3-APMN identification by LC-MS/MS and purification by FPLC
Reactions were carried out using 5 mg NAMPT enzyme, 500 mM 3-AP, 1 mM ATP, 500 mM PRPP in HEPES buffer (50 mM HEPES pH
7.5, 20 mM MgCl2) and incubated for 6 hr at 37 C. Reactions with or without PRPP (obligate cofactor) were stopped by addition of
equal volume of 50% methanol and metabolites were extracted using chloroform. The lyophilized aqueous phase was analyzed by
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LC-MS/MS to identify 3-APMN. 3-APAD was identified similarly from reactions containing both NAMPT and NMNAT1 using LC-MS/
MS. After HPLC separation, 3-APMN was purified through FPLC (Figure S2). In short, an ion-exchange chromatography (IEC) was
carried out on AKTA Purifier (GE HealthCare) using an anion exchange column Source 15Q 4.6/100 PE (GE HealthCare). The column
was equilibrated with 0.01 M ammonium acetate, pH 9.0 at room temperature with a flow rate of 1 ml/min. After injection of the reaction mixture, a linear gradient elution was applied by mixing the 0.01 M and 1 M ammonium acetate, pH 9.0 buffers at 1 ml/min. The
eluate was monitored at wavelength 260 nm. Peaks were collected and lyophilized. Next, lyophilized samples were reconstituted with
5 mM ammonium formate and the identity of 3-APMN peak was confirmed using LC-MS/MS (Agilent, 6470 Triple Quad LC/MS) with a
C18 column (Agilent, EclipsePlus C18, 3.0 3 50mm, 1.8mm particles).
SARM1 activation assay by PC6 fluorescence
Modified from previous paper (Li et al., 2021), typically, in a mixture of 50 ml, 200 ng of SARM1(on-beads) was mixed with 50 mM
PC6, 50 mM NAD+ and 0 to 100 mM of purified 3APMN. The reaction was carried out in a Bio Tek’s Cytation 5 plate reader at 25 C.
Fluorescence signal, which corresponds to PAD6 formation, was recorded with 405 nm excitation and 520 nm emission wavelengths
every 2 minutes. The production rate of PAD6 was calculated based on the fluorescence changes within the first 30 minutes of
reaction.
Metabolite measurement using LC-MS/MS
Lyophilized samples were reconstituted with 50 ml of 5 mM ammonium formate and centrifuged at 12,000 g for 10 min. Cleared supernatants were transferred to sample vials. Serial dilutions of standards for each metabolite in 5 mM ammonium formate were used
for calibration. HPLC-mass spectrometry analysis was performed on an Agilent 1290 Infinity II liquid chromatography system (Agilent
Technologies, Santa Clara, CA) with a flexible pump, multisampler, sample cooler and an MCT containing an Atlantis T3 column
(2.1 3 150 mm, 3 mm) and VanGuard guard cartridge (2.1 mm X 5 mm, 3 mm) (Waters, Milford, MA), coupled to an Agilent 6470 Triple
Quad mass spectrometer (Agilent Technologies, Santa Clara, CA). The mobile phase (0.15 ml/min) was 5 mM ammonium formate in
water (A) and 100% methanol (B). The column was equilibrated with 0% B, maintained after injection for 2 min, then a linear gradient
to 20% B applied over 4 min. The column was then ramped to 50% B over 2 min, and held at 50% for 2 min, then reverted back to 0%
B over the next 5 min and allowed to re-equilibrate at 0% B for 9 min. The total run time was 24 min per sample. The injection volume
was 10 ml. The mass spectrometer was equipped with an electrospray ion source which was operated in positive ion multiple reaction
monitoring (MRM) mode for the detection of all of the metabolites. The [M+H]+ transitions were optimized for each metabolite and
were selected as follows: m/z 664 / 428 for NAD+, m/z 335 / 123 for NMN, m/z 542 / 428 for cADPR, m/z 508 / 136 for ATP, m/z
663 / 136 for 3-APAD and m/z 334 / 122 for 3-APMN. The mass spectrometer settings for the fragmentation, the collision energy
(CE) and the cell accelerator voltage were optimized for each of these transitions. Raw data were acquired and quantified using
MassHunter Workstation software version B.08.00 for 6400 Series Triple Quadrupole (Agilent Technologies, Santa Clara, CA).
IP injection and local application of 3-AP to sciatic nerve using Surgifoam wrap
5 week-old mice were used for IP injection experiment. Suitable skin incisions were made at the mid-thigh level of 5 week-old mice,
followed by a small incision or blunt dissection to the muscle fascia to permit retraction of the biceps femoris and gluteus superficialis
muscles to expose the sciatic nerve. The nerve was carefully separated from surrounding connective tissue and then a 0.5 X 1 cm
piece of sterile absorbable hemostatic material (Surgifoam) soaked in 500 mM 3-AP (or saline control) was wrapped around the
sciatic nerve. Wound clips, and/or tissue adhesive were used to close the incision.
Tissue processing
Tibial nerves from both control and 3-AP treated sides was dissected out 7 days post-surgery. The distal 2 cm portion of the nerve
was fixed in 4% paraformaldehyde for 1 hr at room temperature, then moved to 30% sucrose and embedded in OCT for cryosectioning in the following day. Immunocytochemistry was performed on tibial cryosections using NF200 (Sigma N4142, 1:1000) and
MBP (Millipore MAB386, 1:100) followed by anti-rabbit-Alexa488 (1:500) and anti-rat-Cy3 (1:500). The proximal 2 cm portion of
the sciatic nerves were fixed in 3% Glutaraldehyde for processing and embedding in epoxy/plastic. Toluidine blue thick sections
(400-600 nm thickness) were cut and axon counting was performed using binary image analysis (Hunter et al., 2007).
QUANTIFICATION AND STATISTICAL ANALYSIS
Sample number n represents the number of samples with independent experiments or manipulations. One-way analysis of variance
(ANOVA) were used to make comparisons between samples and two-tailed t tests were used to calculate p value between two
groups and identify statistical significance. Statistical significance was determined by p value. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. All error bars represent standard deviation (SD). Axon degeneration indexes were calculated from distal axons in
brightfield images by an ImageJ macro as described before (Sasaki et al., 2009). All line graphs and boxplots were generated by
R and Graph Pad Prism 7. Boxes represent the interquartile range with horizontal lines indicating the median and whisker lines extending to the maximum and minimum values. All statistical details can be found in the figure legends.
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Figure S1
(A)

(B)

Figure S1. Identification of 3-APMN and 3-APAD by LC-MS/MS (Related to Figure 2 and 3). (A)
3-APMN was identified by LC-MS/MS. Purified NAMPT was incubated with ATP, 3-AP and, with
or without PRPP at 37 °C for 6 hr. The reaction metabolite products were analyzed by LCMS/MS. (B) 3-APAD was identified by LC-MS/MS. Purified NAMPT and NMNAT1 were incubated
with ATP, 3-AP, with or without PRPP at 37 °C overnight. The reaction metabolite products
were analyzed by LC-MS/MS.

Figure S2

Figure S2. Purification of 3-APMN by FPLC (Related to Figure 4). 3-APMN was purified by FPLC
with column Source 15Q, 4.6/100 with flow rate of 1 ml/min using a linear gradient of 10 to 500
mM ammonium acetate, pH 9.0. The identity of the peak as 3-APMN was confirmed by LCMS/MS.

FIgure S3
(A)
****

****

(B)
****

Figure S3. 2-aminopyridine (2-AnP) promotes SARM1-dependent axon degeneration (Related
to Figure 1). (A) Axon degeneration index of WT and Sarm1 KO DRG neurons treated with
indicated concentrations of 2-aminopyridine. Data with error bars correspond to Mean±SD.
Statistical significance was determined by one-way ANOVA tests, comparing to degeneration
index of 0 µM 2-AnP at time 0 hr. ****p < 0.0001. (B) Axon degeneration index of WT DRG
neurons treated with indicated pyridine-related compound. The same concentration (800 µM)
of all compounds were added into neurons. Boxes represent the interquartile range with
horizontal lines indicating the median and whisker lines extending to the maximum and
minimum values. Statistical significance was determined by one-way ANOVA tests (compared to
0 hr). ****p < 0.0001.

